tamoxifen
Over the past 25 years, the       non-steroidal oestrogen antagonist tamoxifen has become the standard endocrine       treatment for breast cancer.
Over the past 25 years, the       non-steroidal oestrogen antagonist  @SUBJECT$  has become the standard endocrine        @PREDICAT$  for  @OBJECT$ .